StreetInsider.com News Articles

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

MAPLE GROVE, Minn., May 20, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS^®(cyclosporine ophthalmic emulsion) 0.05%. According to IQVIA, the cyclosporine ophthalmic emulsion market had U.S. sales of approximately $1.9 billion*. Bora received U.S. Food and Drug Administration (FDA) approval of its abbreviated

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

Form 425 NTN Corp Filed by: NTN Corp

Tue, 12 May 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260512/26475261.html

Form 425 NTN Corp Filed by: NTN Corp

Tue, 12 May 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260512/26475261.html

Form 425 NTN Corp Filed by: NTN Corp

Tue, 12 May 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260512/26475261.html

UPSHER-SMITH LAUNCHES NEW ONLINE RESOURCES TO SUPPORT THE DUCHENNE COMMUNITY

Tue, 14 Apr 2026 10:00:00 -0400

Caregiver and Healthcare Professional Platforms Provide Resources for Initiating and Managing KYMBEE™ (deflazacort) Tablets Treatment

MAPLE GROVE, Minn., April 14, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of dedicated caregiver and healthcare professional (HCP) websites supporting KYMBEE™ (deflazacort) Tablets. KYMBEE™ Tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Manufactured in the

UPSHER-SMITH LAUNCHES NEW ONLINE RESOURCES TO SUPPORT THE DUCHENNE COMMUNITY

Tue, 14 Apr 2026 10:00:00 -0400

Caregiver and Healthcare Professional Platforms Provide Resources for Initiating and Managing KYMBEE™ (deflazacort) Tablets Treatment